Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Cortés J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, Chiu JWY, Pedrini JL, Li W, Yonemori K, Bianchini G, Loi S, Borges GS, Wang X, Bachelot T, Nakatani S, Ashfaque S, Liang Z, Egorov A, Hamilton E. Cortés J, et al. Among authors: yonemori k. Nat Med. 2024 Jun 2. doi: 10.1038/s41591-024-03021-7. Online ahead of print. Nat Med. 2024. PMID: 38825627
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M, Saul M, Le Corre C, Skoura A, Liu L, Li M, LoRusso PM. Mukohara T, et al. Among authors: yonemori k. Nat Med. 2024 Jun 1. doi: 10.1038/s41591-024-03060-0. Online ahead of print. Nat Med. 2024. PMID: 38824244
Trop-2 expression and the tumor immune microenvironment in cervical cancer.
Chiba Y, Kojima Y, Yazaki S, Yoshida H, Takamizawa S, Kitadai R, Saito A, Okuma HS, Nishikawa T, Shimoi T, Sudo K, Noguchi E, Uno M, Ishikawa M, Kato T, Fujiwara Y, Yonemori K. Chiba Y, et al. Among authors: yonemori k. Gynecol Oncol. 2024 May 8;187:51-57. doi: 10.1016/j.ygyno.2024.04.022. Online ahead of print. Gynecol Oncol. 2024. PMID: 38723340
Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.
Imai T, Kojima Y, Shimoi T, Aiba H, Okuma HS, Saito A, Kita S, Yamamoto K, Maejima A, Nishikawa T, Sudo K, Noguchi E, Yoshida A, Matsui Y, Iwata S, Kobayashi E, Kawai A, Udagawa R, Fujiwara Y, Yonemori K. Imai T, et al. Among authors: yonemori k. Anticancer Res. 2024 May;44(5):2125-2132. doi: 10.21873/anticanres.17018. Anticancer Res. 2024. PMID: 38677749
The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology.
Kubo T, Sunami K, Koyama T, Kitami M, Fujiwara Y, Kondo S, Yonemori K, Noguchi E, Morizane C, Goto Y, Maejima A, Iwasa S, Hamaguchi T, Kawai A, Namikawa K, Arakawa A, Sugiyama M, Ohno M, Yoshida T, Hiraoka N, Yoshida A, Yoshida M, Nishino T, Furukawa E, Narushima D, Nagai M, Kato M, Ichikawa H, Fujiwara Y, Kohno T, Yamamoto N. Kubo T, et al. Among authors: yonemori k. ESMO Open. 2024 Apr;9(4):102981. doi: 10.1016/j.esmoop.2024.102981. Epub 2024 Apr 12. ESMO Open. 2024. PMID: 38613908 Free PMC article.
348 results